ArticleBlood advances2024
Jerkeman M, Kolstad A, Hutchings M, et al. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood Adv. 2024;8(2):407-415.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.